The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for prevention of emesis following highly emetogenic chemotherapy (HEC).

Eric  Roeland

Honoraria - Pfizer

Consulting or Advisory Role - AIM Specialty Health; Helsinn Healthcare (Inst); Napo Pharmaceuticals; Oragenics; Pronova (Inst)

Richard J.  Gralla

Honoraria - Chugai Pharma; Helsinn Healthcare; Merck; Mundipharma

Consulting or Advisory Role - Helsinn Healthcare

Research Funding - Merck

Li  Zhang

Consulting or Advisory Role - Boehringer Ingelheim; MSD

Paul Joseph  Hesketh

Research Funding - AstraZeneca (Inst); Roche (Inst)

Lee Steven  Schwartzberg

Honoraria - Amgen; NanoString Technologies; Novartis; Pfizer

Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Genomic Health; Helsinn Therapeutics; Pfizer; Spectrum Pharmaceuticals; Tesaro